• Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden
• The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data
• CNM-Au8 was found to be safe and well-tolerated during the OLE

Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This week, Clene unveiled new and important long-term findings regarding CNM-Au8 treatment’s impact on survival rates and neurofilament light (“NfL”) levels from the HEALEY-ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden (https://ibn.fm/xGfss).

The presentation, titled “Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data extending up to 42 months (3.5 years) and long-term NfL biomarker results over 76 weeks. Analyses included identification of a subset of NfL-responders from the HEALEY ALS Platform Trial. The survival analysis encompassed all participants treated with CNM-Au8 30 mg, including those initially given a placebo who later transitioned to CNM-Au8 in the OLE, provided they had complete baseline co-variates.

The survival analysis included participants originally randomized to receive CNM-Au8 30 mg (n=59) and those who transitioned from placebo to CNM-Au8 (n=11). These groups were compared to matched controls from the PRO-ACT clinical trial database over a follow-up period of up to 3.5 years post-baseline.

• CNM-Au8 30 mg treated patients exhibited approximately a 60% reduction in the risk of death compared to matched PRO-ACT controls over the 3.5-year follow-up period
• The covariate-adjusted hazard ratio was 0.431 (95% CI: 0.276-0.672), with a p-value of 0.0002

A subset analysis identified NfL responders: participants showing consistent NfL declines (n=55). Responders were defined as those having all post-baseline measures with either an NfL decrease or repeated declines of at least 10 pg/mL following the commencement of CNM-Au8 treatment.

• Responders demonstrated an average NfL reduction of 28%, suggesting a therapeutic protection against continued axonal loss
• The geometric mean ratio (“GMR”) at Week 76 compared to baseline was 0.72 (95% CI: 0.67 – 0.79), with a p-value of less than 0.0001

These NfL results stem from previously announced analyses of plasma NfL collected from participants (n=99) in the HEALEY OLE who received CNM-Au8 30 mg up to week 76, compared to those initially on placebo for 24 weeks before switching to active treatment for up to 52 weeks. The analysis of long-term treatment with CNM-Au8 30 mg to week 76 demonstrated that CNM-Au8 continued to significantly reduce plasma NfL levels. The GMR versus placebo at week 76 was 0.841 (95% CI: 0.73 – 0.98), with a p-value of 0.023.

Furthermore, CNM-Au8 was found to be safe and well-tolerated during the OLE.

“The clinical evidence of plasma neurofilament reduction, as well as the long-term improved survival results up to 3.5 years compared to an established multi-study ALS dataset of more than 12,000 patients across multiple clinical centers provides further evidence to strongly support CNM-Au8 as a potential treatment for ALS,” said Dr. Benjamin Greenberg, Head of Medical at Clene.

The full poster is available for viewing in the Scientific Posters & Presentations section of the Clene website https://ibn.fm/njSux).

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• HealthLynked, a leading provider of healthcare technology solutions, recently launched its new online medical record request form, integrated with DocuSign
• The new feature allows patients to seamlessly and securely request their medical records from doctors’ offices, hospitals, and laboratories with just a few clicks
• Through the feature, HealthLynked aims to solve inefficiencies and security issues affecting the flow of health information, helping patients share their medical records with their doctors directly
• The HIPAA, through the Privacy Rule, aims to allow the flow of health information that can help health care providers to provide high-quality health care and to protect the public’s health and well-being

The Standards for Privacy of Individually Identifiable Health Information (“Privacy Rule”), issued by the U.S. Department of Health and Human Services (“HHS”) to implement the requirement of the Health Insurance Portability and Accountability Act (“HIPAA”) of 1996, aims to, among others, allow the “flow of health information needed to provide and promote high-quality health care and to protect the public’s health and well-being.” It permits crucial uses of health information while protecting the privacy of patients (https://ibn.fm/S9hpp).

However, a 2018 Yale study found that American hospitals complicate the process by which patients access medical records. The study reported that many top hospitals in the country “are making it unduly confusing or expensive for patients to gain access to their own medical records.” This is despite the fact that HIPAA and supporting rules guarantee patients access to their protected information in a timely fashion and in the format the patient wants.

“There were overwhelming inconsistencies in information relayed to patients regarding the personal health information they are allowed to request, as well as the formats and costs of release, both within institutions and across institutions,” YaleNews quoted Carolyn Lye, the first author on the study, as saying (https://ibn.fm/bVpok).

The inconsistencies, inefficiencies, and delays in the record sharing process has been sighted by many as one of the main problems within the healthcare system.  As a result, HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology solutions, has developed, as part of its comprehensive healthcare network, a medical record storage facility designed to solve inefficiencies and data security issues. The company recently launched its new online medical record request form, integrated with DocuSign. This cutting-edge feature is part of the company’s HealthLynked Network. It allows patients to seamlessly request their medical records from doctors’ offices, hospitals, and laboratories with just a few clicks (https://ibn.fm/oBDl2).

Once transmitted, the requested records are automatically uploaded to the patients’ respective HealthLynked Network profiles, allowing patients to easily access their own records virtually as well as quickly and easily share them with health care providers when needed. In this regard, the addition of the records to the patients’ profiles creates a centralized, easily accessible, manageable, and shareable repository of individual and collective health data. According to the company, users of the free package can store up to five records, while paid members enjoy unlimited record storage.

“The development of the online medical record request form is a testament to our commitment to leveraging the latest technology to improve patient care. By digitizing and streamlining the process of obtaining medical records, we are making it more user-friendly and compliant with healthcare regulations. Access to more medical records that patients can share with their doctors directly leads to better, more informed patient care,” said Chris Hall, CTO of HealthLynked.

HealthLynked reports that the integration with DocuSign, a pioneer in electronic signature technology, ensures that all requests are secure and encrypted, safeguarding patient confidentiality. The integration also promotes convenience by providing an easy-to-use method of confirming patients’ identities.

“We are thrilled to offer this new feature to our users. By integrating with DocuSign, we are not only enhancing the efficiency and security of medical record requests but also ensuring compliance with digital health standards. This makes it easier for patients to manage their health information, ultimately leading to better patient care through more comprehensive access to medical records,” conveyed Dr. Michael Dent, CEO of HealthLynked.

The HealthLynked Network is a patient-centric medical network that allows users to store their medical information, receive assistance with medical forms and questions, book appointments with any doctor, access telemedicine services anywhere in the country, chat with a nurse, obtain copies of lab results, co-manage family members’ healthcare, and much more.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

• PayPal reported a 9.4% increase in top-line revenue and a 14% year-over-year growth in total payment volume, highlighting its robust growth trajectory
• The company’s strategic initiatives, including the expansion of Venmo and the introduction of new features like Fastlane, are poised to drive further growth and user engagement
• Despite competition from Apple, PayPal maintains a dominant market share in online payments, with strategic focuses that underscore its competitive edge and resilience

PayPal Holdings (NASDAQ: PYPL), a leading digital payments platform, has been navigating through a period of strong growth amidst a challenging macroeconomic landscape. With a vast user base and a reputation for innovation in the fintech sector, PayPal has established itself as a key player in the digital payments space, competing directly with giants like Apple (NASDAQ: AAPL). Despite facing stiff competition, particularly with Apple’s introduction of new fintech features, PayPal’s recent financial performance and strategic initiatives indicate a robust growth trajectory.

In the first quarter, PayPal reported a notable 9.4% increase in top-line revenue, reaching $7.7 billion, and a 14% year-over-year growth in total payment volume, which hit $404 billion. These figures underscore the company’s ability to expand its operations and attract more transactions across its platform, even in a tough economic environment. The growth in payment transactions per active account, which rose by 13% year-over-year, further demonstrates PayPal’s success in engaging its user base and enhancing transaction frequency.

PayPal’s strategic focus on expanding its services is evident in the growth of its Venmo service, which now boasts 60 million active monthly users in the U.S. The introduction of new features, such as the guest checkout system Fastlane, is expected to drive payment volume and attract first-time users. The emphasis on increasing debit card adoption, which generates nearly 20% more revenue per user than non-debit card users, is a testament to PayPal’s commitment to monetizing its user base effectively. These efforts, coupled with a favorable market valuation with a forward price-to-earnings ratio of 14 times, position PayPal for sustained growth.

Despite the competitive pressures from Apple’s fintech initiatives, PayPal’s dominant market share in online payments, standing at 56% compared to Apple’s 12.6%, suggests resilience in the face of potential market share erosion. The company’s comprehensive suite of payment solutions and its strategic focus on user engagement and monetization through services like Venmo and Fastlane underscore its competitive edge. Moreover, the recent “buy” rating from New Street Research, based on the potential for increased payment volume and improved profit margins, highlights the confidence in PayPal’s growth prospects and its ability to navigate competitive challenges.

Currently trading at $59.78, PayPal’s stock has experienced fluctuations within a narrow range, reflecting the market’s mixed sentiment towards the company’s future amidst increased competition and macroeconomic uncertainties. With a market capitalization of about $62.53 billion and a trading volume of 4,905,062 shares on the NASDAQ exchange, PayPal remains a significant player in the digital payments industry. Despite the short- to medium-term challenges, the company’s strong fundamentals, strategic growth initiatives, and solid financial performance suggest that PayPal’s shares could offer strong returns over the long term, making it a stock to watch in the evolving fintech landscape.

For more information, visit the company’s website at www.PayPal.com.

ROTH is excited to invite companies, entrepreneurs, industries, and businesses to attend the 10th Annual ROTH London Conference, taking place from June 25-27, 2024, at the Four Seasons Hotel London at Park Lane. This event is a premier gathering for small-cap companies, providing significant growth and networking opportunities.

The conference will feature 1-to-1 meetings lasting 40 minutes each, allowing investors and companies to engage in-depth on various sectors, including sustainability, agtech, E&P, metals and mining, and technology. These intimate group meetings are designed to facilitate detailed discussions and valuable connections.

In addition to these meetings, the conference will include presentations from key figures such as Michael Darda, Chief Economist and Market Strategist, and JC O’Hara, Chief Technical Strategist at ROTH. Their presentation on Market Strategy and Overview will be held on June 26, 2024.

This event has a strong reputation, with past conferences drawing hundreds of participants, including institutional investors, family offices, high-net-worth individuals, and equity analysts. Notable attendees include seasoned investors, shareholders, and leading management teams from various industries across Europe.

For startups and new businesses, the conference offers a unique platform to explore opportunities within the global investment community. Attendees will benefit from the insights and strategies shared by experts and have the chance to network with influential figures from multiple sectors.

For more information and to register for the conference, visit the ROTH website.

Companies interested in scheduling one-on-one meetings can contact their ROTH representative directly​.

CannaCon Midwest St. Paul invites like-minded entrepreneurs, investors, public officials, patients, and enthusiasts of the cannabis spectrum, to attend the CannaCon Midwest St. Paul conference August 16-17, 2024. This event is a one-stop solution for the cannabis community looking for resources, education, and collaboration opportunities, for all things cannabis.

The CannaCon conference offers a phenomenal platform for enthusiasts, creatives, growers, and traders in and around the venue, to stay updated with the latest industry trends and develop the best networking connections. They will find the latest cultivation techniques, genetics, supplies, unique industry innovations, business, financial, and legal advice, marketing, branding and more, all under one roof.

World-class leaders and veterans of the cannabis trade will grace the event with their presence. Exhibitors will set up booths at the expo showcasing their latest offerings and innovative ideas. Investors looking for new investment opportunities will find a plethora of potential leads on the exhibitor floor. The event offers one-to-one meetings among entrepreneurs, executives, and investors for an in-depth understanding of the goals and vision of both parties.

Apart from the expo, the event will showcase speaker sessions and panel discussions featuring Former Governor and pro wrestler Jesse Ventura. He will interact with the audience, answer their queries, and offer insightful tips. CannaCon is a global networking forum where cannabis businesses and investors connect to discover new talent and develop long-term collaborations. This event promises greater trade and opportunities for cannabis industries in the region.

New as well as seasoned entrepreneurs pitch their businesses at their exhibitor booths to avail the enormous reach and connections that the CannaCon conferences offer. The event organizers ensure exhibitors have all the requisite resources at their disposal for setting up their booths.

To learn more, please visit https://ibn.fm/1NRZ5

• Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2
• The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration
• The study’s main objective is to evaluate Lexaria’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug, semaglutide, currently commercially available as Rybelsus(R)
• The commencement of the pilot study shows Lexaria’s commitment to its promise to focus on GLP-1 studies for 2024, along with its confidence in its DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2, GLP-1-H24-2. The study aims to evaluate the company’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1) drug semaglutide, which is currently commercially available in the branded product Rybelsus(R) (https://ibn.fm/5GcOz).

This second round of dosing utilized Rybelsus processed with DehydraTECH and is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database (“FDA IID”), which was administered with swallowed capsules. All nine study participants were successfully dosed, building on the initial study arm, which used a positive control Rybelsus swallowed tablet, whereas the third arm will explore an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.

This third and final study arm will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can be absorbed into the bloodstream at any level systemically into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed pill administration. This study is set to be completed in early July. If successful, this study will help remedy the downsides of swallowed administration, which is heavily impacted by the stomach’s acidic environment. This environment significantly degrades GLP-1 drugs swallowed, resulting in meager blood absorption rates of less than 1% when absorption technology is not used.

This move aligns with Lexaria’s plan to focus on GLP-1 studies for the 2024 calendar year. It also speaks to its commitment and overall confidence in the potential of its DehydraTECH technology. It is an important milestone for the company, mainly since, at the very beginning, the GLP-1 studies were considered a “high-risk” program, according to its CEO, Chris Bunka. This was mainly attributed to the fact that the study fell under a class of drugs considered “large molecules,” a class that the company had never explored before, especially given its focus on “small molecules” (https://ibn.fm/275ZI).

So far, Lexaria has achieved great success with its GLP-1 studies. In addition, the rising interest in GLP-1 drugs, owing to their health benefits, has seen the company double down on this research going forward. The successful completion of the second round of dosing for its GLP-H24-2 human pilot study indicates this commitment while ushering in what’s to come for the company.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Many older adults are at risk of developing mental-health conditions, including depression and anxiety disorders
• NCOA reports that “fewer than 50% of older adults with mental and/or substance-use disorders receive treatment”
• Astiva Health is committed to providing strategic, enhanced mental-health services for seniors to help them identify and effectively treat mental-health challenges

As baby boomers continue to reach their “golden” years, the number of older adults grappling with mental illness also continues to increase. Astiva Health is committed to providing enhanced mental-health services for its members, as more seniors face mental disorders.

“The world’s population is ageing fast,” reports the World Health Organization (https://ibn.fm/ghYHj). “In 2020, 1 billion people in the world were aged 60 years or over. That figure will rise to 1.4 billion by 2030, representing one in six people globally. By 2050, the number of people aged 60 years and over will have doubled to reach 2.1 billion. The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.”

While most of these aging adults enjoy good health, many are at risk of developing mental-health conditions, including depression and anxiety disorders. “Around 14% of adults aged 60 and over live with a mental disorder,” WHO reported. “According to the Global Health Estimates 2019, these conditions account for 10.6% of the total disability among older adults. The most common mental-health conditions for older adults are depression and anxiety. GHE 2019 shows that globally, around a quarter of deaths from suicide (27.2%) are among people aged 60 or over.”

The National Council on Aging (“NCOA”) has reported that the stressors caused by the COVID-19 pandemic have increased mental-health service needs for older adults (https://ibn.fm/5RtlR). “Fewer than 50% of older adults with mental and/or substance-use disorders receive treatment,” the agency reports. “Improving mental health care for older adults requires changes such as strengthening the mental health workforce, continued expansion of Medicare coverage of tele-health visits, parity between physical and mental health care, and increased Older Americans Act funding.”

In another report (https://ibn.fm/CPiZK), the NCOA noted that “barriers that keep many older adults from accessing supportive mental health services include denial, lack of information or knowledge, personal financial imitations, limited state and federal funding, waiting lists and biases. Yet overcoming those barriers is key to improving older adult mental health.” The agency emphasized that access to mental health services can allow older adults to live independently and improve quality of life and that there is a need for more mental-health and substance use disorder providers that specialize in older adults.

“Meet older adults with mental services where they are instead of expecting them to navigate complex systems and requirements,” the report noted. “And understand the impact of isolation on physical and mental health for older adults.” Numerous studies (https://ibn.fm/hunh4), have shown the impact that community support has on both the physical and mental health of seniors (https://ibn.fm/L4aha).

Dedicated to meeting its older members where they are, Astiva Health offers a dynamic and innovative Medicare Advantage Prescription Drug (“MAPD”) health plan focused on reshaping the landscape of personalized and comprehensive healthcare. The company is committed to providing strategic, enhanced mental-health services for seniors to help them identify and effectively treat their mental-health challenges.

Astiva Health cares about its members and works to establish lifelong relationships with members by providing a tailored approach to healthcare. That tailored approach includes offering multilingual solutions for customer service, marketing materials and educational resources. Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Through acquisition, management has agreed to use 10% of the profits from logistics business to buy back and retire GTVH stock
• “This transition marks a pivotal moment in our journey,” states exec
• Management is crafting a comprehensive business plan that substantially expands the company’s growth trajectory

Golden Triangle Ventures (OTC: GTVH) continues to take strategic steps toward expanding and positioning the company for fundamental business income and financial independence. The latest in these steps is the completed acquisition of Cargo Management Group, a multifaceted logistics and trucking operation (https://ibn.fm/o80WE). According to the announcement, through this acquisition, management has agreed to use 10% of the profits from its logistics business to buy back and retire GTVH stock, effectively reducing the number of outstanding shares on a consistent basis as profits are realized. The buyback will commence once the full transition of the logistics business is complete and profits of the business can be realized.

A complete shipping, logistics and trucking operation, Cargo Management Group will be a key component in providing support for GTVH’s Lavish Entertainment division. With the acquisition completed, Golden Triangle is now focused on facilitating the company’s assumption of full ownership of the logistics operation, brokerage business, licenses and all associated assets.

“We are confident about successfully implementing our initiatives, maintaining profitability and significantly scaling the operation,” said Lavish Entertainment president and COO Marco Antonio Moreno. “Our goal is to secure premium, dedicated, high-paying lanes, upgrade our existing equipment, strengthen all operations and expand our business into more lucrative markets, which further supports our other internal projects. This transition marks a pivotal moment in our journey, as we are now boots on the ground working towards a seamless integration, transition and a complete business enhancement on all fronts.”

The acquisition of Cargo Management Group brings a time-tested, proven performer into the Golden Triangle community. Cargo Management Group reported close to $3 million in top-line revenue last year. In addition, the company currently has contracts with numerous prominent corporations, including JB Hunt, CH Robinson, Coyote Logistics and Echo Logistics. Cargo Management Group also holds high-paying specialized loads in the gaming industry to transport slot machines to locations nationwide.

Short-term, GTVH and Cargo Management Group are focused on defining the structure and transition strategy for combining a high-performing shipping and logistics operation into GTVH. In addition, key team leaders are crafting a comprehensive business plan that builds on the strengths of the combined companies, which will substantially expand the company’s growth trajectory. Specifically, the plan will include incorporating all types of trucking freight movements and adding heavy haul to the services offered by GTVH and Cargo Management Group.

“This initiative marks the first of several strategies we plan to implement that aim to optimize our capital structure within GTVH,” said Steffan Dalsgaard, Golden Triangle Ventures president. “Our goal is to develop true fundamental business activities that support all our operations. We have successfully implemented the first part of our four-pillar business model that supports Lavish Entertainment and our flagship Destino Ranch project, and our team is now focused on executing a series of other promising developments. These efforts are designed to further our objective of increasing shareholder value across all facets of our company.”

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, along with other sectors that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• Emperor Metals is growing the historic mineral resource of 727,000 ounces of high-grade gold at 5.42 g/t Au and an impressive 5.71 m avg thickness
• Emperor used artificial intelligence and machine learning to create the first 3D & geological model last year, leading it to discover potential for extending an open pit mine above the high-grade underground lenses on which it had previously focused
• The company has approximately $4 million in working capital to advance its project toward an updated mineral resource later this year
• Mobilization on an 8,000-meter drill program, coupled with an 8,000-meter core sampling project in the open pit, began last month for this year’s effort

Advanced stage gold explorer Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH) is looking forward to proving and developing the substantial resource potential of its flagship Duquesne West Gold Project in southwest Quebec, Canada, with this year’s drilling program. 

“Our drilling program is basically going to be 70-80 percent looking at the open pit potential. 20-30  percent is going to be looking at those high-grade lenses in the underground,” Emperor Metals President and CEO John Florek said during a Paydirt Prospector interview last month (https://ibn.fm/ySZpI).

“Now keep in mind, when we introduced this to investors it was just a high-grade underground gold deposit. The revelation last year was that (there may be) potential for a large-scale open pit above it,” Florek said. “So we did some pit optimization. … It’s exciting to have a big open pit deposit above a high-grade underground gold (resource).” 

Florek said the company had begun mobilizing to go back to the historical core and sample within the open pit, doing an 8,000-meter drill program underground along with 8,000 meters of core sampling, trying to add inferred ounces to extend the open pit boundaries.

“Because (the open pit boundary) is really kind of still open to the east and to the west,” he said. “But we also want to drill some of that underground stuff because right below the open pit is those underground, high-grade ounces.”

The site in the historic Duparquet gold mining camp in the southern part of the Abitibi Greenstone Belt of Rouyn-Noranda, some 500 km northwest of Canada’s capital city of Ottawa, hosts an estimated historical mineral resource (2011) of 727,000 ounces of gold at a grade of 5.42 g/t Au.

Last year, the company used artificial intelligence and machine learning to reinterpret the existing geological model and guide its successful drilling campaign, creating “the first 3D mineralized and geological model” the company stated in a news release last month (https://ibn.fm/s2w0e).

Gold has been posting market gains in recent months and hit a new all-time high of US$2,427 per ounce in May (https://ibn.fm/GWnOr). Major emerging market economies, primarily in Asia, have been increasing their consumption of gold in recent years, centered around China which has historically been the world’s largest consumer of gold but with expectations that Singapore will be the new hub of world gold trading (https://ibn.fm/LA9iM).

The world trends and the resource discoveries at the Quebec site bode well for Emperor’s future.

“Emperor is well funded with approximately $4 million in working capital and will advance the Duquesne West Project towards an updated mineral resource,” Florek said in last month’s news release. “Gold prices continue to show strength, and we are confident that everything is now in place to give our shareholders the best chance of a successful upside on this project.”

For more information, visit the company’s website at www.EmperorMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMAUF are available in the company’s newsroom at https://ibn.fm/EMAUF

• Recent report projects global cannabis market to reach $444.34 billion by 2030
• MedCana and its subsidiaries are focused on establishing stronghold in this expanding space
• MedCana is committed to advancing cannabis production and agricultural technology around the world, while also driving innovation and promoting sustainability

The cannabis industry continues to grow, as it has consistently for the past several years. Recent projections value the global cannabis market at almost $445 billion by 2030 (https://ibn.fm/YRTbo). This is good news for Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ), a leading entity in the cannabis and agricultural technology sectors. Recently, MedCana noted remarkable advancements across its diverse portfolio, which includes five companies focused on pharmaceutical cannabis production, as well as a software company focused on managing processes for plant-to-patient operations (https://ibn.fm/WeqNt).

“The global cannabis market size is projected to grow from $57.18 billion in 2023 to $444.34 billion by 2030, at a CAGR of 34.03% during the forecast period,” reported Fortune Business Insights, which noted that cannabis has been used for thousands of years for its therapeutic and medicinal benefits. “Marijuana legalization is gaining momentum across the globe. This momentum is driven primarily by increasing recognition that the product may have a range of legitimate medicinal benefits and therapeutic applications. It is the most widely cultivated, trafficked and consumed drug worldwide.”

MedCana is focused on positioning itself in this expanding space. The company reports that its subsidiaries are seeing significant success in different parts of the world. Several business units are currently in the final stages of negotiations to determine specific varietals to export to Europe and Australia; both countries are expected to see significant growth in their cannabis markets in coming years. In addition, the company’s South American subsidiary, Eko2o Environmental Solutions S.A.S., is rapidly expanding its reach within the agricultural industry, specifically eyeing growth in the Costa Rica and Central American markets (https://ibn.fm/ofzpf).

Clearly, MedCana is poised for growth and profitability. The company’s deliberate decision to focus on cannabis production is bearing fruit, with operations working to meet the stringent quality and regulatory standards of the European and Australian markets. When these standards are met, the resulting expansion is expected to significantly boost MedCana’s international presence and open new avenues for growth.

“We are delighted with the progress we’ve made across all fronts,” said MedCana CEO Jose Gabriel Diaz. “The final negotiations for cannabis exportation and the rapid expansion of Eko2o’s technology distribution mark a significant milestone in our journey. We are now closer than ever to achieving profitability and solidifying our position as industry leaders.”

MedCana is committed to advancing cannabis production and agricultural technology around the world, while also driving innovation and promoting sustainability. As the company moves forward with its strategic growth plans, stakeholders can expect to see enhanced profitability and a stronger global presence.

Software Effective Solutions/MedCana is a holding company focused on developing companies in the agricultural technology and cannabis industries. The company remains dedicated to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ